Mesenchymal stem cells (MSCs) hold many advantages over embryonic stem cells (ESCs) and other somatic cells in clinical applications. MSCs are multipotent cells with strong immunosuppressive properties. They can be harvested from various locations in the human body (e.g., bone marrow and adipose tissues). Cryopreservation represents an efficient method for the preservation and pooling of MSCs, to obtain the cell counts required for clinical applications, such as cell-based therapies and regenerative medicine. Upon cryopreservation, it is important to preserve MSCs functional properties including immunomodulatory properties and multilineage differentiation ability. Further, a biosafety evaluation of cryopreserved MSCs is essential prior to their clinical applications. However, the existing cryopreservation methods for MSCs are associated with notable limitations, leading to a need for new or improved methods to be established for a more efficient application of cryopreserved MSCs in stem cell-based therapies. We review the important parameters for cryopreservation of MSCs and the existing cryopreservation methods for MSCs. Further, we also discuss the challenges to be addressed in order to preserve MSCs effectively for clinical applications.
Get full access to this article
View all access options for this article.
References
1.
ArthurA, ZannettinoA, GronthosS. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol, 2009; 218:237–245.
EstrovZ. Stem cells and somatic cells: Reprogramming and plasticity. Clin Lymphoma Myeloma., 2009; 9:S319–328.
4.
RichardsonSM, HoylandJA, MobasheriR, et al.Mesenchymal stem cells in regenerative medicine: Opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol, 2010; 222:23–32.
5.
LindroosB, SuuronenR, MiettinenS. The potential of adipose stem cells in regenerative medicine. Stem Cell Rev, 2011; 7:269–291.
6.
YoungFE. A time for restraint. Science, 2000; 287:1424.
7.
GinisI, GrinblatB, ShirvanMH. Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium. Tissue Eng Part C Methods, 2012; 18:453–463.
8.
PravdyukAI, PetrenkoYA, FullerBJ, et al.Cryopreservation of alginate encapsulated mesenchymal stromal cells. Cryobiology, 2013; 66:215–222.
9.
De RosaA, De FrancescoF, TirinoV, et al.A new method for cryopreserving adipose-derived stem cells: An attractive and suitable large-scale and long-term cell banking technology. Tissue Eng Part C Methods, 2009; 15:659–667.
10.
MinonzioG, CorazzaM, MariottaL, et al.Frozen adipose-derived mesenchymal stem cells maintain high capability to grow and differentiate. Cryobiology, 2014; 69:211–216.
11.
FerrettiC, BorsariV, FalconiM, et al.Human periosteum-derived stem cells for tissue engineering applications: The role of VEGF. Stem Cell Rev, 2012; 8:882–890.
12.
AngeloPC, FerreiraAC, FonsecaVD, et al.Cryopreservation does not alter karyotype, multipotency, or NANOG/SOX2 gene expression of amniotic fluid mesenchymal stem cells. Genet Mol Res, 2012; 11:1002–1012.
13.
LiuG, YeX, ZhuY, et al.Osteogenic differentiation of GFP-labeled human umbilical cord blood derived mesenchymal stem cells after cryopreservation. Cryobiology, 2011; 63:125–128.
14.
CallihanP, MumawJ, MachacekDW, et al.Regulation of stem cell pluripotency and differentiation by G protein coupled receptors. Pharmacol Ther, 2011; 129:290–306.
15.
DoulatovS, DaleyGQ. Development. A stem cell perspective on cellular engineering. Science, 2013; 342:700–702.
16.
De MiguelMP, Fuentes-JulianS, Blazquez-MartinezA, et al.Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med, 2012; 12:574–591.
KimN, ImKI, LimJY, et al.Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: Experiments and practice. Ann Hematol, 2013; 92:1295–1308.
DaviesOG, SmithAJ, CooperPR, et al.The effects of cryopreservation on cells isolated from adipose, bone marrow and dental pulp tissues. Cryobiology, 2014; 69:342–347.
21.
MagalhaesR, Anil KumarPR, WenF, et al.The use of vitrification to preserve primary rat hepatocyte monolayer on collagen-coated poly(ethylene-terephthalate) surfaces for a hybrid liver support system. Biomaterials, 2009; 30:4136–4142.
22.
GoldringCE, DuffyPA, BenvenistyN, et al.Assessing the safety of stem cell therapeutics. Cell Stem Cell, 2011; 8:618–628.
23.
StubbanC, KatkovI, LoringJF, et al.Chapter 4. Cryopreservation of human embryonic stem cells. In: SchwartzJFLLWH, ed; Human Stem Cell Manual.Oxford Academic Press; 2007, pp. 47–55.
24.
RowleySD. Hematopoietic stem cell cryopreservation: A review of current techniques. J Hematother, 1992; 1:233-250.
25.
RowleySD., FengZ, ChenL, et al.A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant, 2003; 31:1043–1051.
26.
KofronMD, OpsitnickNC, AttawiaMA, et al.Cryopreservation of tissue engineered constructs for bone. J Orthop Res, 2003; 21:1005–1010.
27.
WagnerCT, MartowiczML, LiveseySA, et al.Biochemical stabilization enhances red blood cell recovery and stability following cryopreservation. Cryobiology, 2002; 45:153–166.
28.
AngerJT, GilbertBR, GoldsteinM. Cryopreservation of sperm: Indications, methods and results. J Urol, 2003; 170:1079–1084.
29.
ChinSP, PoeyAC, WongCY, et al.Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy. Cytotherapy, 2010; 12:31–37.
30.
Castelo-BrancoMT, SoaresID, LopesDV, et al.Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS One, 2012; 7:e33360.
31.
RagoonananV, HubelA, AksanA. Response of the cell membrane-cytoskeleton complex to osmotic and freeze/thaw stresses. Cryobiology, 2010; 61:335–344.
32.
WoodburyD, SchwarzEJ, ProckopDJ, et al.Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res, 2000; 61:364–370.
33.
GuvenS, DemirciU. Integrating nanoscale technologies with cryogenics: A step towards improved biopreservation. Nanomedicine (Lond), 2012; 7:1787–1789.
34.
BerzD, McCormackEM, WinerES, et al.Cryopreservation of hematopoietic stem cells. Am J Hematol, 2007; 82:463–472.
SamuelssonH, RingdenO, LonniesH, et al.Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy, 2009; 11:129–136.
43.
FrancoisM, CoplandIB, YuanS, et al.Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy, 2012; 14:147–152.
44.
MollG, AlmJJ, DaviesLC, et al.Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?. Stem Cells, 2014; 32:2430–2442.
45.
LuetzkendorfJ, NergerK, HeringJ, et al.Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. Cytotherapy, 2015; 17:186–198.
46.
de Lima PrataK, de SantisGC, OrellanaMD, et al.Cryopreservation of umbilical cord mesenchymal cells in xenofree conditions. Cytotherapy, 2012; 14:694–700.
47.
ChoiJ, Pingguan-MurphyB., Wan AbasWA, et al.Impact of low oxygen tension on stemness, proliferation and differentiation potential of human adipose-derived stem cells. Biochem Biophys Res Commun, 2014; 448:218–224.
48.
ChuaKH, Zaman Wan SafwaniWK, HamidAA, et al.Retropatellar fat pad-derived stem cells from older osteoarthritic patients have lesser differentiation capacity and expression of stemness genes. Cytotherapy, 2014; 16:599–611.
49.
Wan SafwaniWK, MakpolS, SathapanS, et al.The changes of stemness biomarkers expression in human adipose-derived stem cells during long-term manipulation. Biotechnol Appl Biochem, 2011; 58:261–270.
50.
Janz FdeL, Debes AdeA, Cavaglieri RdeC, et al.Evaluation of distinct freezing methods and cryoprotectants for human amniotic fluid stem cells cryopreservation. J Biomed Biotechnol, 2012; 2012:649353.
51.
Miranda-SayagoJM, Fernandez-ArcasN, BenitoC, et al.Evaluation of a low cost cryopreservation system on the biology of human amniotic fluid-derived mesenchymal stromal cells. Cryobiology, 2012; 64:160–166.
52.
ThirumalaS, WuX, GimbleJM, et al.Evaluation of polyvinylpyrrolidone as a cryoprotectant for adipose tissue-derived adult stem cells. Tissue Eng Part C Methods, 2010; 16:783–792.
53.
Al-SaqiSH, SaliemM, QuezadaHC, et al.Defined serum- and xeno-free cryopreservation of mesenchymal stem cells. Cell Tissue Bank, 2015; 16:181–193.
54.
LiuG, ZhouH, LiY, et al.Evaluation of the viability and osteogenic differentiation of cryopreserved human adipose-derived stem cells. Cryobiology, 2008; 57:18–24.
55.
GondaK, ShigeuraT, SatoT, et al.Preserved proliferative capacity and multipotency of human adipose-derived stem cells after long-term cryopreservation. Plast Reconstr Surg, 2008; 121:401–410.
56.
JamesAW, LeviB, NelsonER, et al.Deleterious effects of freezing on osteogenic differentiation of human adipose-derived stromal cells in vitro and in vivo. Stem Cells Dev, 2011; 20:427–439.
57.
KarlssonJO, TonerM. Long-term storage of tissues by cryopreservation: Critical issues. Biomaterials, 1996; 17:243–256.
58.
ThirumalaS, GimbleJM, DevireddyRV. Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum-free freezing media for cryopreservation of adipose-derived adult stem cells. Stem Cells Dev, 2010; 19:513–522.
59.
PittengerMF, MackayAM, BeckSC, et al.Multilineage potential of adult human mesenchymal stem cells. Science, 1999; 284:143–147.
60.
ChoiJR, Pingguan-MurphyB, Wan AbasWA, et al.In situ normoxia enhances survival and proliferation rate of human adipose tissue-derived stromal cells without increasing the risk of tumourigenesis. PLoS One, 2015; 10:e0115034.
61.
ZhangHT, ChenH, ZhaoH, et al.Neural stem cells differentiation ability of human umbilical cord mesenchymal stromal cells is not altered by cryopreservation. Neurosci Lett, 2011; 487:118–122.
62.
DominiciM, Le BlancK, MuellerI, et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006; 8:315–317.
63.
ChoiJR, Pingguan-MurphyB, AbasWABW, et al.Hypoxia promotes growth and viability of human adipose-derived stem cells with increased growth factors secretion. J Asian Sci Res, 2014; 4:328–338.
64.
MartinelloT, BronziniI, MaccatrozzoL, et al.Canine adipose-derived-mesenchymal stem cells do not lose stem features after a long-term cryopreservation. Res Vet Sci, 2011; 91:18–24.
65.
SeoJM, SohnMY, SuhJS, et al.Cryopreservation of amniotic fluid-derived stem cells using natural cryoprotectants and low concentrations of dimethylsulfoxide. Cryobiology, 2011; 62:167–173.
66.
FinkDWJr.FDA regulation of stem cell-based products. Science, 2009; 324:1662–1663.
LaurentLC, UlitskyI, SlavinI, et al.Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell, 2011; 8:106–118.
69.
HanahanD, WeinbergRA. Hallmarks of cancer: The next generation. Cell, 2011; 144:646–674.
70.
DittmarKE, SimannM, ZghoulN, et al.Quality of cell products: Authenticity, identity, genomic stability and status of differentiation. Transfus Med Hemother, 2010; 37:57–64.
NelissenEC, van MontfoortAP, DumoulinJC, et al.Epigenetics and the placenta. Hum Reprod Update, 2011; 17:397–417.
73.
SacksteinR. The lymphocyte homing receptors: Gatekeepers of the multistep paradigm. Curr Opin Hematol, 2005; 12:444–450.
74.
LiY, ChenJ, ChenXG, et al.Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology, 2002; 59:514–523.
75.
ChinnaduraiR, GarciaMA, SakuraiY, et al.Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Stem Cell Reports, 2014; 3:60–72.
76.
XuX, LiuY, CuiZ, et al.Effects of osmotic and cold shock on adherent human mesenchymal stem cells during cryopreservation. J Biotechnol, 2012; 162:224–231.
77.
RolligC, BabatzJ, WagnerI, et al.Thawing of cryopreserved mobilized peripheral blood—Comparison between waterbath and dry warming device. Cytotherapy, 2002; 4:551–555.
78.
ThirumalaS, ZvonicS, FloydE, et al.Effect of various freezing parameters on the immediate post-thaw membrane integrity of adipose tissue derived adult stem cells. Biotechnol Prog, 2005; 21:1511–1524.
79.
ZhangX, CatalanoPN, GurkanUA, et al.Emerging technologies in medical applications of minimum volume vitrification. Nanomedicine (Lond), 2011; 6:1115–1129.
80.
WowkB. Electric and magnetic fields in cryopreservation. Cryobiology, 2012; 64:301–303.
81.
LeeSY, HuangGW, ShiungJN, et al.Magnetic cryopreservation for dental pulp stem cells. Cells Tissues Organs, 2012; 196:23–33.
82.
YongKW, Pingguan-MurphyB, XuF, et al.Phenotypic and functional characterization of long-term cryopreserved human adipose-derived stem cells. Sci Rep, 2015; 5:9596.
83.
LiY, TanJC, LiLS. Comparison of three methods for cryopreservation of human embryonic stem cells. Fertil Steril, 2010; 93:999–1005.
84.
Martin-IbanezR, HovattaO, CanalsJM. Cryopreservation of human pluripotent stem cells: Are we going in the right direction? In: KatkovI, ed; Current Frontiers in Cryobiology. InTech; 2012. pp. 139–166.
85.
ZambelliA, PoggiG, Da PradaG, et al.Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res, 1998; 18:4705–4708.
86.
SonJH, HeoYJ, ParkMY, et al.Optimization of cryopreservation condition for hematopoietic stem cells from umbilical cord blood. Cryobiology, 2010; 60:287–292.
87.
TuschongL, SoenenSL, BlaeseRM, et al.Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther, 2002; 13:1605–1610.
88.
VerdanovaM, PytlikR, KalbacovaMH. Evaluation of sericin as a fetal bovine serum-replacing cryoprotectant during freezing of human mesenchymal stromal cells and human osteoblast-like cells. Biopreserv Biobank, 2014; 12:99–105.
89.
RallWF, FahyGM. Ice-free cryopreservation of mouse embryos at −196 degrees C by vitrification. Nature, 1985; 313:573–575.
90.
MoonJH, LeeJR, JeeBC, et al.Successful vitrification of human amnion-derived mesenchymal stem cells. Hum Reprod, 2008; 23:1760–1770.
91.
SongYS, AdlerD, XuF, et al.Vitrification and levitation of a liquid droplet on liquid nitrogen. Proc Natl Acad Sci USA, 2010; 107:4596–4600.
92.
FountainD, RalstonM, HigginsN, et al.Liquid nitrogen freezers: A potential source of microbial contamination of hematopoietic stem cell components. Transfusion, 1997; 37:585–591.
93.
TedderRS, ZuckermanMA, GoldstoneAH, et al.Hepatitis B transmission from contaminated cryopreservation tank. Lancet, 1995; 346:137–140.
94.
AbdelHafezF, XuJ, GoldbergJ, et al.Vitrification in open and closed carriers at different cell stages: assessment of embryo survival, development, DNA integrity and stability during vapor phase storage for transport. BMC Biotechnol, 2011; 11:29.
95.
SamotJ, MoonS, ShaoL, et al.Blood banking in living droplets. PLoS One, 2011; 6:e17530.
96.
SongYS, MoonS, HulliL, et al.Microfluidics for cryopreservation. Lab Chip, 2009; 9:1874–1881.
97.
ParmegianiL, CognigniGE, FilicoriM. Ultra-violet sterilization of liquid nitrogen prior to vitrification. Hum Reprod, 2009; 24:2969.
98.
XuF, MoonS, ZhangX, et al.Multi-scale heat and mass transfer modelling of cell and tissue cryopreservation. Philos Trans A Math Phys Eng Sci, 2010; 368:561–583.
